000894084 001__ 894084
000894084 005__ 20240701202017.0
000894084 0247_ $$2doi$$a10.3390/ijms22126553
000894084 0247_ $$2ISSN$$a1422-0067
000894084 0247_ $$2ISSN$$a1661-6596
000894084 0247_ $$2Handle$$a2128/28209
000894084 0247_ $$2pmid$$a34207233
000894084 0247_ $$2WOS$$aWOS:000665922100001
000894084 037__ $$aFZJ-2021-03030
000894084 082__ $$a540
000894084 1001_ $$0P:(DE-Juel1)165908$$aSchemmert, Sarah$$b0
000894084 245__ $$aIn Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease
000894084 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2021
000894084 3367_ $$2DRIVER$$aarticle
000894084 3367_ $$2DataCite$$aOutput Types/Journal article
000894084 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719815255_31265
000894084 3367_ $$2BibTeX$$aARTICLE
000894084 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000894084 3367_ $$00$$2EndNote$$aJournal Article
000894084 520__ $$aMultiple sources of evidence suggest that soluble amyloid β (Aβ)-oligomers are responsible for the development and progression of Alzheimer’s disease (AD). In order to specifically eliminate these toxic Aβ-oligomers, our group has developed a variety of all-d-peptides over the past years. One of them, RD2, has been intensively studied and showed such convincing in vitro and in vivo properties that it is currently in clinical trials. In order to further optimize the compounds and to elucidate the characteristics of therapeutic d-peptides, several rational drug design approaches have been performed. Two of these d-peptides are the linear tandem (head-to-tail) d-peptide RD2D3 and its cyclized form cRD2D3. Tandemization and cyclization should result in an increased in vitro potency and increase pharmacokinetic properties, especially crossing the blood–brain-barrier. In comparison, cRD2D3 showed a superior pharmacokinetic profile to RD2D3. This fact suggests that higher efficacy can be achieved in vivo at equally administered concentrations. To prove this hypothesis, we first established the in vitro profile of both d-peptides here. Subsequently, we performed an intraperitoneal treatment study. This study failed to provide evidence that cRD2D3 is superior to RD2D3 in vivo as in some tests cRD2D3 failed to show equal or higher efficacy.
000894084 536__ $$0G:(DE-HGF)POF4-323$$a323 - Molecular Targets & Therapies (POF4-323)$$cPOF4-323$$fPOF IV$$x0
000894084 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x1
000894084 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000894084 7001_ $$0P:(DE-Juel1)176380$$aCamargo, Luana Cristina$$b1$$ufzj
000894084 7001_ $$0P:(DE-Juel1)164541$$aHonold, Dominik$$b2
000894084 7001_ $$0P:(DE-Juel1)171922$$aGering, Ian$$b3
000894084 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b4
000894084 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b5
000894084 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b6$$eCorresponding author
000894084 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms22126553$$gVol. 22, no. 12, p. 6553 -$$n12$$p6553 -$$tInternational journal of molecular sciences$$v22$$x1422-0067$$y2021
000894084 8564_ $$uhttps://juser.fz-juelich.de/record/894084/files/ijms-22-06553-v2.pdf$$yOpenAccess
000894084 8767_ $$8101453$$92021-06-16$$d2021-08-13$$eAPC$$jZahlung erfolgt$$zBelegnr. 1200170623
000894084 909CO $$ooai:juser.fz-juelich.de:894084$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$popenaire$$pOpenAPC$$popen_access
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165908$$aForschungszentrum Jülich$$b0$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176380$$aForschungszentrum Jülich$$b1$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164541$$aForschungszentrum Jülich$$b2$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171922$$aForschungszentrum Jülich$$b3$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b4$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b5$$kFZJ
000894084 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b6$$kFZJ
000894084 9131_ $$0G:(DE-HGF)POF4-323$$1G:(DE-HGF)POF4-320$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lUmweltbedingte und metabolische Erkrankungen$$vMolecular Targets & Therapies$$x0
000894084 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x1
000894084 9141_ $$y2021
000894084 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000894084 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000894084 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2019$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000894084 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000894084 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000894084 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000894084 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000894084 980__ $$ajournal
000894084 980__ $$aVDB
000894084 980__ $$aI:(DE-Juel1)IBI-7-20200312
000894084 980__ $$aI:(DE-Juel1)INM-4-20090406
000894084 980__ $$aAPC
000894084 980__ $$aUNRESTRICTED
000894084 9801_ $$aAPC
000894084 9801_ $$aFullTexts